Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine

PLoS Pathogens

Volumn 9, Issue 4, 2013, Pages

  Ross, Pádraig J ^a   Sutton, Caroline E ^a   Higgins, Sarah ^a   Allen, Aideen C ^a   Walsh, Kevin ^a   Misiak, Alicja ^a   Lavelle, Ed C ^a   McLoughlin, Rachel M ^a   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD11B ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CRYOPYRIN; CXCL1 CHEMOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; PERTUSSIS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NEUTROPHIL; NONHUMAN; PERTUSSIS; RESPIRATORY TRACT INFECTION; TH1 CELL; TH17 CELL;

ADAPTIVE IMMUNITY; ALUM COMPOUNDS; ANIMALS; BORDETELLA PERTUSSIS; IMMUNITY, CELLULAR; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PERTUSSIS VACCINE; TH1 CELLS; TH17 CELLS; VACCINATION; WHOOPING COUGH;

BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS; MUS;

EID: 84876841020     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003264     Document Type: Article

References (64)

1. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, et al. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 334: 341-348.
2. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J, (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334: 349-355.
3. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, et al. (1997) A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15: 1606-1612.
4. Cherry JD, (2010) The present and future control of pertussis. Clin Infect Dis 51: 663-667.
5. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987.
6. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R, (2012) Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367: 1012-1019.
7. Storsaeter J, Hallander HO, Gustafsson L, Olin P, (1998) Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16: 1907-1916.
8. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, et al. (1998) Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93: 1-10.
9. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A, (1997) Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 65: 2168-2174.
10. Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH, (1997) Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med 186: 1843-1851.
11. Barbic J, Leef MF, Burns DL, Shahin RD, (1997) Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect Immun 65: 4904-4908.
12. Mills KH, Ryan M, Ryan E, Mahon BP, (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66: 594-602.
13. Redhead K, Watkins J, Barnard A, Mills KH, (1993) Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61: 3190-3198.
14. Mahon BP, Brady MT, Mills KH, (2000) Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis 181: 2087-2091.
15. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH, (2006) TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 177: 7980-7989.
16. Dunne A, Ross PJ, Pospisilova E, Masin J, Meaney A, et al. (2010) Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol 185: 1711-1719.
17. Fedele G, Spensieri F, Palazzo R, Nasso M, Cheung GY, et al. (2010) Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways. PLoS One 5: e8734.
18. Andreasen C, Powell DA, Carbonetti NH, (2009) Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 4: e7079.
19. Lambrecht BN, Kool M, Willart MA, Hammad H, (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21: 23-29.
20. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA, (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122-1126.
21. Li H, Willingham SB, Ting JP, Re F, (2008) Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181: 17-21.
22. Franchi L, Nunez G, (2008) The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38: 2085-2089.
23. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC, (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203: 1685-1691.
24. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, et al. (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30: 576-587.
25. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, et al. (2011) Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 186: 5738-5748.
26. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, et al. (2001) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194: 519-527.
27. Mills KH, Barnard A, Watkins J, Redhead K, (1993) Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61: 399-410.
28. Barnard A, Mahon BP, Watkins J, Redhead K, Mills KH, (1996) Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 87: 372-380.
29. Xing DK, Das RG, Williams L, Canthaboo C, Tremmil J, et al. (1999) An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine 17: 565-576.
30. Church MA, (1979) Evidence of whooping-cough-vaccine efficacy from the 1978 whooping-cough epidemic in Hertfordshire. Lancet 2: 188-190.
31. Report (1982) Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 Area Health Authorities. Br Med J (Clin Res Ed) 285: 357-359.
32. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H, (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350: 1569-1577.
33. Mattoo S, Cherry JD, (2005) Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18: 326-382.
34. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, et al. (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31: 331-341.
35. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
36. Mahon BP, Mills KH, (1999) Interferon-gamma mediated immune effector mechanisms against Bordetella pertussis. Immunol Lett 68: 213-217.
37. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, et al. (1997) Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 175: 1246-1250.
38. Mascart F, Verscheure V, Malfroot A, Hainaut M, Pierard D, et al. (2003) Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 170: 1504-1509.
39. Ausiello CM, Lande R, la Sala A, Urbani F, Cassone A, (1998) Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J Infect Dis 178: 466-470.
40. Peppoloni S, Nencioni L, Di Tommaso A, Tagliabue A, Parronchi P, et al. (1991) Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect Immun 59: 3768-3773.
41. Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, et al. (2008) Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun 76: 1257-1266.
42. Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH, (2000) Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. ClinExpImmunol 121: 193-200.
43. White OJ, Rowe J, Richmond P, Marshall H, McIntyre P, et al. (2010) Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 28: 2648-2652.
44. Zepp F, Knuf M, Habermehl P, Schmitt JH, Rebsch C, et al. (1996) Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 64: 4078-4084.
45. Rowe J, Yerkovich ST, Richmond P, Suriyaarachchi D, Fisher E, et al. (2005) Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 73: 8130-8135.
46. Ausiello CM, Lande R, Urbani F, la Sala A, Stefanelli P, et al. (1999) Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 67: 4064-4071.
47. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, et al. (2008) IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol 181: 4965-4975.
48. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5: e1000703.
49. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, et al. (2009) Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136: 2237-2246 e2231.
50. Cunningham CC, Mills E, Mielke LA, O'Farrell LK, Lavelle E, et al. (2012) Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase. Clin Immunol 144: 228-236.
51. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
52. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, et al. (2009) Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183: 4403-4414.
53. Peral de Castro C, Jones SA, Ni Cheallaigh C, Hearnden CA, Williams L, et al. (2012) Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. J Immunol 189: 4144-4153.
54. Sutton CE, Mielke LA, Mills KH, (2012) IL-17-producing gammadelta T cells and innate lymphoid cells. Eur J Immunol 42: 2221-2231.
55. Zhang X, Hester SE, Kennett MJ, Karanikas AT, Bendor L, et al. (2011) Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun 79: 527-541.
56. Andreasen C, Carbonetti NH, (2009) Role of neutrophils in response to Bordetella pertussis infection in mice. Infect Immun 77: 1182-1188.
57. Harvill ET, Cotter PA, Miller JF, (1999) Pregenomic comparative analysis between bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection. Infect Immun 67: 6109-6118.
58. Mills KH, (2008) Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 38: 2636-2649.
59. Rennels MB, Black S, Woo EJ, Campbell S, Edwards KM, (2008) Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr Infect Dis J 27: 464-465.
60. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, et al. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2: 52ra72.
61. Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, et al. (2005) A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23: 5450-5456.
62. Asokanathan C, Corbel M, Xing D, (2013) A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Hum Vaccin Immunother 9[Epub ahead of print].
63. McGuirk P, McCann C, Mills KH, (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195: 221-231.
64. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, et al. (2003) Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol 171: 3119-3127.